Log in

NASDAQ:QCOR - Questcor Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.
Read More
Questcor Pharmaceuticals logo

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:QCOR
CUSIP74835Y10
Phone+1-714-7864200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive QCOR News and Ratings via Email

Sign-up to receive the latest news and ratings for QCOR and its competitors with MarketBeat's FREE daily newsletter.


Questcor Pharmaceuticals (NASDAQ:QCOR) Frequently Asked Questions

Has Questcor Pharmaceuticals been receiving favorable news coverage?

Headlines about QCOR stock have been trending somewhat positive on Saturday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Questcor Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutQuestcor Pharmaceuticals.

Who are some of Questcor Pharmaceuticals' key competitors?

What other stocks do shareholders of Questcor Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Questcor Pharmaceuticals investors own include Baidu (BIDU), Netflix (NFLX), Mastercard (MA), Qihoo 360 Technology (QIHU), Celgene (CELG), Alphabet (GOOG), Tesla (TSLA), 3D Systems (DDD), Michael Kors (KORS) and First Solar (FSLR).

What is Questcor Pharmaceuticals' stock symbol?

Questcor Pharmaceuticals trades on the NASDAQ under the ticker symbol "QCOR."

What is Questcor Pharmaceuticals' official website?

The official website for Questcor Pharmaceuticals is http://www.mallinckrodt.com/.

How can I contact Questcor Pharmaceuticals?

Questcor Pharmaceuticals' mailing address is 1300 N Kellogg Dr Ste D, ANAHEIM, CA 92807-1965, United States. The biopharmaceutical company can be reached via phone at +1-714-7864200.


MarketBeat Community Rating for Questcor Pharmaceuticals (NASDAQ QCOR)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  502
MarketBeat's community ratings are surveys of what our community members think about Questcor Pharmaceuticals and other stocks. Vote "Outperform" if you believe QCOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QCOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel